QUERCETIN POTENTIATES THE EFFECT OF ADRIAMYCIN IN A MULTIDRUG-RESISTANT MCF-7 HUMAN BREAST-CANCER CELL-LINE - P-GLYCOPROTEIN AS A POSSIBLE TARGET

被引:257
作者
SCAMBIA, G
RANELLETTI, FO
PANICI, PB
DEVINCENZO, R
BONANNO, G
FERRANDINA, G
PIANTELLI, M
BUSSA, S
RUMI, C
CIANFRIGLIA, M
MANCUSO, S
机构
[1] UNIV CATTOLICA SACRO CUORE, DEPT GYNECOL, I-00168 ROME, ITALY
[2] UNIV CATTOLICA SACRO CUORE, DEPT HISTOL, ROME, ITALY
[3] UNIV CATTOLICA SACRO CUORE, DEPT PATHOL, ROME, ITALY
[4] UNIV CATTOLICA SACRO CUORE, DEPT HEMATOL, ROME, ITALY
[5] ISS ROME, DEPT IMMUNOL, ROME, ITALY
关键词
QUERCETIN; ADRIAMYCIN; MULTIDRUG RESISTANCE; HUMAN BREAST CANCER CELLS;
D O I
10.1007/BF00685655
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study demonstrates that the flavonoid quercetin (Q), a plant-derived compound with low toxicity in vivo, greatly potentiates the growth-inhibitory activity of Adriamycin (ADR) on MCF-7 ADR-resistant human breast cancer cells. The effect of Q was dose-dependent at concentrations ranging between 1 and 10 mu M. Since ADR resistance in these cells is associated with the expression of high levels of P-glycoprotein (Pgp), we evaluated the effect of Q and related flavonoids of Pgp activity in cytofluorographic efflux experiments with the fluorescent dye rhodamine 123 (Rh 123). Our results indicate that Q and 3-OMe Q (3',4',7-trimethoxyquercetin) but not the 3-rhamnosylglucoside of Q (rutin) inhibit the Pgp pump-efflux activity in a dose-related manner. Moreover, 10 mu M Q reduces the expression of the immunoreactive Pgp in MCF-7 ADR-resistant cells as evaluated by cytofluorimetric assay. In conclusion, these findings provide a further biological basis for the potential therapeutic application of Q as an anticancer drug either alone or in combination with ADR in multidrug-resistant breast tumor cells.
引用
收藏
页码:459 / 464
页数:6
相关论文
共 42 条
[1]  
Adrian L. H., 1992, ACTA ONCOL, V31, P205
[2]  
CIANFRIGLIA M, 1994, INT J CANCER, V56, P153
[3]   REVERSAL OF ADRIAMYCIN RESISTANCE BY LONIDAMINE IN A HUMAN BREAST-CANCER CELL-LINE [J].
CITRO, G ;
CUCCO, C ;
VERDINA, A ;
ZUPI, G .
BRITISH JOURNAL OF CANCER, 1991, 64 (03) :534-536
[4]   PHARMACOLOGICAL AND SUPRAPHARMACOLOGICAL CONCENTRATIONS OF BOTH 17-BETA-ESTRADIOL AND TAMOXIFEN REDUCE THE MEMBRANE FLUIDITY OF MCF-7 AND MDA-MB-436 HUMAN-BREAST CANCER-CELLS [J].
CLARKE, R ;
VANDENBERG, HW ;
NELSON, J ;
MURPHY, RF .
BIOCHEMICAL SOCIETY TRANSACTIONS, 1987, 15 (02) :243-244
[5]   ADVERSE INTERACTIONS BETWEEN CYTO-TOXIC DRUGS AND HORMONAL AGENTS IN HUMAN-BREAST CANCER-CELLS [J].
CLARKE, R ;
VANDENBERG, HW .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (10) :1580-1581
[6]   MULTIDRUG RESISTANCE ACTIVITY IN HUMAN-LYMPHOCYTES [J].
COON, JS ;
WANG, YZ ;
BINES, SD ;
MARKHAM, PN ;
CHONG, ASF ;
GEBEL, HM .
HUMAN IMMUNOLOGY, 1991, 32 (02) :134-140
[7]  
DEFFIE AM, 1989, CANCER RES, V49, P58
[8]  
DEFFIE AM, 1988, CANCER RES, V48, P3595
[9]   TOREMIFENE - PHARMACOLOGIC AND PHARMACOKINETIC BASIS OF REVERSING MULTIDRUG RESISTANCE [J].
DEGREGORIO, MW ;
FORD, JM ;
BENZ, CC ;
WIEBE, VJ .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (09) :1359-1364
[10]  
EFFERTH T, 1989, ANTICANCER RES, V9, P1633